1	Serological detection of SARS-CoV-2 lgG using commercially available immunoassays on
2	dried blood spots collected from patients
3	Gregory J Walker ^{1,2,3} , Rebecca Davis ⁴ , Zin Naing ³ , Brad McEntee ⁵ , Yonghui Lu ³ , Tatijana
4	Denadija ⁴ , William D Rawlinson ^{1,2,3,6}
5	Affiliations:
6	¹ Virology Research Laboratory, Serology and Virology Division, NSW Health Pathology SEALS
7	Randwick, NSW 2031, Australia
8	² School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney,
9	NSW 2052, Australia
10	³ Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital,
11	Sydney, NSW 2031, Australia
12	4 Department of Microbiology and Infectious Diseases, NSW Health Pathology, Royal Prince
13	Alfred Hospital, NSW
14	⁵ Special Health Accommodation, Sydney Local Health District, NSW
15	⁶ School of Biotechnology and Biomolecular Sciences (BABS) Faculty of Science, University of
16	New South Wales, Sydney, NSW 2052, Australia
17	*Corresponding author: Prof William Rawlinson, Virology Research Laboratory, Level 3
18	Clinical Sciences Building, Prince of Wales Hospital, Randwick 2031, Australia.
19	E-mail: w.rawlinson@unsw.edu.au Ph: +61 2 93829188
20	Running title: SARS-CoV-2 lgG detection from dried blood spots

21 ABSTRACT

22 Serological testing for SARS-CoV-2 antibodies provides important research and diagnostic 23 information relating to COVID-19 immune response and surveillance. A major challenge 24 when addressing protection post- infection or vaccination is the difficulty of specimen collection from infants and children. Dried blood spots (DBS) collected by finger prick or heel 25 prick are a minimally invasive sample collection alternative previously used to detect 26 27 antibodies to other viruses. In this study we evaluated DBS for the detection of SARS-CoV-2 28 antibodies on three commercially available enzyme (EIA) and chemiluminescent (CLIA) 29 immunoassays by analysing paired DBS and serum samples collected from 54 subjects. We 30 demonstrate that testing of DBS samples was highly sensitive and specific, and quantitative results strongly correlated with those of paired serum. These results suggest that DBS 31 32 derived blood is a viable alternative to plasma or serum for use in EIAs and CLIAs, and has 33 particular utility as a minimally invasive collection tool for COVID-19 serological testing of 34 infants and children.

36 Serological methods for SARS-CoV-2 antibody detection are routinely performed on plasma 37 or serum from peripherally collected venous blood. This can be inconvenient and often 38 unacceptable to children. Dried blood spots (DBS) collected by finger prick or heel prick are 39 a minimally-invasive alternative previously used to detect antibodies against Epstein-Barr, 40 HIV, Hepatitis, Rubella and other viruses (1). Evaluation of DBS for the detection of SARS-41 CoV-2 antibodies on commercially available enzyme (EIA) and chemiluminescent (CLIA) 42 immunoassays was performed by analysing paired DBS and serum samples from 54 subjects 43 aged between 5 and 73 years.

44 Whole blood was collected from patients via venepuncture and spotted onto DBS cards (Whatman 903 Protein Saver), with the remainder put into a serum tube. DBS were then 45 processed (Supplementary materials) and tested in parallel with matched sera for 46 47 antibodies against SARS-CoV-2 using the spike-based ARCHITECT SARS-CoV-2 IgG II Quantitative Assay (Abbott Laboratories, Abbott Park, IL, USA), and the S1 spike- and 48 49 nucleocapsid-based Euroimmun Anti-SARS-CoV-2 ELISA (Euroimmun, Lübeck, Germany) 50 assays, following manufacturer's instructions. The ARCHITECT SARS-CoV-2 IgG II Quantitative Assay records data as arbitrary units (AU), and these results were interpreted 51 52 as positive (\geq 50 AU/mL) and negative (<50 AU/mL). For Euroimmun assays, the ratio of 53 sample absorbance over the calibrator (OD ratio) was used to categorise sample results as positive (\geq 1.1), equivocal (1.1> OD \geq 0.8), and negative (<0.8). Samples returning an 54 55 equivocal result were excluded from sensitivity and specificity calculations in this analysis. 56 Sensitivity and specificity were calculated using results of parallel testing on peripherally 57 collected serum samples as the reference standard. Concordance between quantitative 58 measurements were calculated with Pearson's Correlation Coefficient.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.11.21261877; this version posted August 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

59 For the spike-based ARCHITECT and Euroimmun assay there were no discordant results 60 between any of the 54 paired samples. On both assays DBS testing displayed 100% 61 sensitivity and 100% specificity with reference to matched serum. The correlation 62 coefficients between quantitative serum and DBS measurements were r= 0.9662 (0.9421 -0.9803, p<0.0001) and r= 0.9831 (0.9708 - 0.9902, p< 0.0001), respectively (Figure). On a 63 64 subset of 46 matched samples tested on the Euroimmun nucleocapsid-based assay there 65 was one discordant result, and DBS testing exhibited 100% sensitivity. One of 5 pairs that had a negative result on serum testing was positive on DBS testing. The correlation 66 67 coefficient between quantitative serum and DBS measurements were r= 0.9075 (0.8380 -68 0.9480, p<0.0001).

69



70

Figure. Linear regression of CLIA arbitrary units per millilitre (AU/mL) or EIA optical density (OD) ratios for the detection of anti-SARS-CoV-2 lgG in 54 paired dried blood spot (DBS) and serum samples. Samples were run on the ARCHITECT SARS-CoV-2 lgG II Quantitative Assay (A), and the Euroimmun Anti-SARS-CoV-2 ELISA S1 spike (B) and nucleocapsid assays (C). Dotted lines indicate the positive/negative, negative/equivocal, and equivocal/positive cutoffs of respective assays.

78 The high sensitivity and specificity of DBS tests and strong quantitative relationship with 79 paired serum on the spike-based ARCHITECT CLIA and Euroimmun EIA demonstrates the 80 validity of DBS collection for the detection of SARS-CoV-2 antibodies on these assays. This is 81 the first study to validate the quantitative ARCHITECT assay for DBS testing, and the first to 82 include paediatric specimens in analysis (Supplementary materials). Our findings also 83 confirm those of recent studies in which adult DBS were validated using semi-quantitative 84 ElAs targeting the S1 spike (2-4) and nucleocapsid proteins (3-5). These data suggest DBS 85 derived blood is a viable alternative to plasma or serum collection. It has particular utility for 86 testing infants and children, and in hotel or home quarantine where sample collection is 87 performed away from clinical settings. It can reduce transmission risks to staff collecting samples from infected patients, as less time needs to be spent with the child to obtain the 88 89 sample. Additionally, this non-invasive tool collection tool is well suited to COVID-19 90 surveillance.

92 References

93	1.	Amini F, Auma E, Hsia Y, et al. Reliability of dried blood spot (DBS) cards in antibody	
94	measu	rement: A systematic review. PLOS ONE. 2021;16(3):e0248218.	
95	2.	Amendola A, Bianchi S, Gori M, et al. Dried Blood Spot as an Alternative to	
96	Plasma	a/Serum for SARS-CoV-2 IgG Detection, an Opportunity to Be Sized to Facilitate	
97	COVID-19 Surveillance Among Schoolchildren. The Pediatric Infectious Disease Journal.		
98	2021;40(1):e46-e7.		
99	3.	Weisser H, Steinhagen K, Höcker R, Borchardt-Lohölter V, Anvari Ö, Kern PM.	
100	Evalua	tion of dried blood spots as alternative sampling material for serological detection of	
101	anti-SA	ARS-CoV-2 antibodies using established ELISAs. Clinical Chemistry and Laboratory	
102	Medic	ine (CCLM). 2021;59(5):979-85.	
103	4.	Zava TT, Zava DT. Validation of dried blood spot sample modifications to two	
104	comm	ercially available COVID-19 IgG antibody immunoassays. Bioanalysis. 2021;13(1):13-	
105	28.		
106	5.	Mulchandani R, Brown B, Brooks T, et al. Use of dried blood spot samples for SARS-	
107	CoV-2	antibody detection using the Roche Elecsys ® high throughput immunoassay. Journal	
108	of clini	cal virology : the official publication of the Pan American Society for Clinical Virology.	
109	2021;1	136:104739	

110

112	Supplementary Material
113	Serological detection of SARS-CoV-2 lgG using a commercially available enzyme
114	immunoassays on dried blood spots collected from patients
115	Gregory J Walker, Rebecca Davis, Zin Naing, Brad McEntee, Yonghui Lu, Tatijana Denadija,
116	William D Rawlinson
117	Corresponding author: Prof William Rawlinson, Virology Research Laboratory, Level 3
118	Clinical Sciences Building, Prince of Wales Hospital, Randwick 2031, Australia.
119	E-mail: w.rawlinson@unsw.edu.au Ph: +61 2 93829188
120	
121	This file includes:
122	Supplementary methods. Processing of dried blood spot samples
123	Table S1. Age distribution of patients sampled

125 Processing of dried blood spot samples

126	Whole blood was collected from patients via venepuncture and spotted onto Whatman 903 Protein
127	Saver DBS cards. DBS samples were then processed by methods applicable to each assay platform.
128	For the ARCHITECT SARS-CoV-2 IgG II Quantitative Assay (Abbott Laboratories, Abbott Park, IL, USA)
129	a 6mm spot was punched using a standard office hole punch and transferred to a 2 ml round bottom
130	centrifuge tube. After 300 μl of 0.25% Tergitol 15-S-9 in PBS was added, the sample tube was
131	incubated on an orbital shaker at 400 rpm for 60 min, followed by a centrifugation at 10,000g for 10
132	min. Supernatant (130 μL) was then transferred to a sample cup and loaded onto ARCHITECT <code>i2000SR</code>
133	analyzer for testing. As the current on-market ARCHITECT SARS-CoV-2 IgG II Quantitative Assay is not
134	claimed for DBS use, a Research Use Only (RUO) assay file was installed to facilitate the DBS sample
135	measurement. The DBS method for this platform may be further modified to improve agreement
136	with quantitative serum results.
137	For the Euroimmun Anti-SARS-CoV-2 ELISA (Euroimmun, Lübeck, Germany) assays, a single 4.76mm
138	disk was punched and incubated in 250 μ L of ELISA buffer (kit component) for one hour at 37°C. The
139	eluted solution was then pipette mixed thoroughly and 100uL was taken forward for analysis as per

140 the manufacturer's instructions.

141 **Table S1.** Age distribution of patients sampled

Age	n=
All	54
5-12	4
13-18	4
19-40	29
41-60	12
>60	5